Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model
<b>Background/Objectives</b>: Breast cancer remains a leading cause of cancer-related mortality among women worldwide, necessitating novel therapeutic strategies. This study aimed to investigate the synergistic antitumor effects of caerin peptides (F1/F3) combined with dendritic cell (DC...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/6/577 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850164941451952128 |
|---|---|
| author | Rongmi Mo Junjie Li Xinyi Song Jiawei Fu Mengqi Liu Yuandong Luo Quanlan Fu Jinyi Wu Hongyin Wu Yongxin Liang Tianfang Wang Xiaosong Liu Guoying Ni |
| author_facet | Rongmi Mo Junjie Li Xinyi Song Jiawei Fu Mengqi Liu Yuandong Luo Quanlan Fu Jinyi Wu Hongyin Wu Yongxin Liang Tianfang Wang Xiaosong Liu Guoying Ni |
| author_sort | Rongmi Mo |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Breast cancer remains a leading cause of cancer-related mortality among women worldwide, necessitating novel therapeutic strategies. This study aimed to investigate the synergistic antitumor effects of caerin peptides (F1/F3) combined with dendritic cell (DC) vaccines in a 4T-1 murine breast cancer model, providing new insights for breast cancer immunotherapy. <b>Methods</b>: In vitro experiments evaluated the effects of F1/F3 on 4T-1 cell proliferation and apoptosis. A 4T-1 breast cancer mouse model was established, and treatments included F1/F3 alone, DC vaccines (DCV<sub>1</sub>: loaded with whole tumor antigens; DCV<sub>2</sub>: loaded with F1/F3-induced apoptotic antigens), or combination therapy. Flow cytometry analyzed immune cell subsets in the tumor microenvironment and lymph nodes, while ELISA measured cytokine levels. <b>Results</b>: F1/F3 significantly inhibited 4T-1 cell proliferation and induced apoptosis while suppressing tumor growth and lung metastasis in vivo. Flow cytometry revealed increased infiltration of CD4<sup>+</sup> T cells and cDC<sub>1</sub> in tumors, along with reduced PD-L1 expression. DCV<sub>2</sub> exhibited stronger T-cell proliferation induction and lower IL-10 secretion in vitro. Combination therapy with DCV<sub>2</sub> and F1/F3 demonstrated superior tumor suppression compared to monotherapy. <b>Conclusions</b>: F1/F3 enhances antitumor immunity by modulating the tumor microenvironment, and its combination with DCV<sub>2</sub> yields synergistic effects. This study provides experimental evidence for combination immunotherapy in breast cancer, with potential for further optimization of DC vaccine design to improve efficacy. |
| format | Article |
| id | doaj-art-7931f295b7f24afca91eade08049a16d |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-7931f295b7f24afca91eade08049a16d2025-08-20T02:21:51ZengMDPI AGVaccines2076-393X2025-05-0113657710.3390/vaccines13060577Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer ModelRongmi Mo0Junjie Li1Xinyi Song2Jiawei Fu3Mengqi Liu4Yuandong Luo5Quanlan Fu6Jinyi Wu7Hongyin Wu8Yongxin Liang9Tianfang Wang10Xiaosong Liu11Guoying Ni12The First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, ChinaZhongao Biomedical Technology (Guangdong) Co., Ltd., Zhongshan 528400, ChinaThe First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, ChinaThe First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, ChinaMedical College, Guizhou University, Guiyang 550025, ChinaZhongao Biomedical Technology (Guangdong) Co., Ltd., Zhongshan 528400, ChinaZhongao Biomedical Technology (Guangdong) Co., Ltd., Zhongshan 528400, ChinaThe First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, ChinaThe First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, ChinaCancer Research Institute, Foshan First People’s Hospital, Foshan 528000, ChinaCentre for Bioinnovation, University of the Sunshine Coast, Maroochydore, QLD 4558, AustraliaThe First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, ChinaThe First Affiliated Hospital, Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou 510080, China<b>Background/Objectives</b>: Breast cancer remains a leading cause of cancer-related mortality among women worldwide, necessitating novel therapeutic strategies. This study aimed to investigate the synergistic antitumor effects of caerin peptides (F1/F3) combined with dendritic cell (DC) vaccines in a 4T-1 murine breast cancer model, providing new insights for breast cancer immunotherapy. <b>Methods</b>: In vitro experiments evaluated the effects of F1/F3 on 4T-1 cell proliferation and apoptosis. A 4T-1 breast cancer mouse model was established, and treatments included F1/F3 alone, DC vaccines (DCV<sub>1</sub>: loaded with whole tumor antigens; DCV<sub>2</sub>: loaded with F1/F3-induced apoptotic antigens), or combination therapy. Flow cytometry analyzed immune cell subsets in the tumor microenvironment and lymph nodes, while ELISA measured cytokine levels. <b>Results</b>: F1/F3 significantly inhibited 4T-1 cell proliferation and induced apoptosis while suppressing tumor growth and lung metastasis in vivo. Flow cytometry revealed increased infiltration of CD4<sup>+</sup> T cells and cDC<sub>1</sub> in tumors, along with reduced PD-L1 expression. DCV<sub>2</sub> exhibited stronger T-cell proliferation induction and lower IL-10 secretion in vitro. Combination therapy with DCV<sub>2</sub> and F1/F3 demonstrated superior tumor suppression compared to monotherapy. <b>Conclusions</b>: F1/F3 enhances antitumor immunity by modulating the tumor microenvironment, and its combination with DCV<sub>2</sub> yields synergistic effects. This study provides experimental evidence for combination immunotherapy in breast cancer, with potential for further optimization of DC vaccine design to improve efficacy.https://www.mdpi.com/2076-393X/13/6/577caerin 1.1/1.9DC vaccineTMEDLNs4T-1 |
| spellingShingle | Rongmi Mo Junjie Li Xinyi Song Jiawei Fu Mengqi Liu Yuandong Luo Quanlan Fu Jinyi Wu Hongyin Wu Yongxin Liang Tianfang Wang Xiaosong Liu Guoying Ni Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model Vaccines caerin 1.1/1.9 DC vaccine TME DLNs 4T-1 |
| title | Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model |
| title_full | Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model |
| title_fullStr | Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model |
| title_full_unstemmed | Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model |
| title_short | Synergistic Antitumor Effects of Caerin Peptides and Dendritic Cell Vaccines in a 4T-1 Murine Breast Cancer Model |
| title_sort | synergistic antitumor effects of caerin peptides and dendritic cell vaccines in a 4t 1 murine breast cancer model |
| topic | caerin 1.1/1.9 DC vaccine TME DLNs 4T-1 |
| url | https://www.mdpi.com/2076-393X/13/6/577 |
| work_keys_str_mv | AT rongmimo synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT junjieli synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT xinyisong synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT jiaweifu synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT mengqiliu synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT yuandongluo synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT quanlanfu synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT jinyiwu synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT hongyinwu synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT yongxinliang synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT tianfangwang synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT xiaosongliu synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel AT guoyingni synergisticantitumoreffectsofcaerinpeptidesanddendriticcellvaccinesina4t1murinebreastcancermodel |